z-logo
open-access-imgOpen Access
Kajian Potensi Interaksi Obat pada Pasien COVID-19 di Rumah Sakit X Kota Samarinda
Author(s) -
Shofia Siza Maulidia,
Febrina Mahmudah,
Yurika Sastyarina
Publication year - 2021
Publication title -
proceeding of mulawarman pharmaceuticals conferences
Language(s) - English
Resource type - Journals
ISSN - 2614-4778
DOI - 10.25026/mpc.v14i1.587
Subject(s) - polypharmacy , covid-19 , medicine , drug , pandemic , medical record , disease , emergency medicine , infectious disease (medical specialty) , pharmacology
Coronavirus disease 2019 (COVID-19) is a respiratory infectious disease caused by a coronavirus known as SARS-CoV-2 and is currently a worldwide pandemic. Treatment management for COVID-19 patients is grouped based on the level of symptoms experienced by the patient. The use of large amounts of drugs (polypharmacy) in COVID-19 patients with moderate and severe symptoms can increase the possibility of drug interactions. This study aims to determine patient characteristics and the potential for drug interactions in COVID-19 patients at Hospital X Samarinda City. The data collection method was conducted retrospectively based on the medical records of COVID-19 patients hospitalized from March to December 2020. Data on potential drug interactions were analyzed using the Drugs.com application. The results showed that of the 30 patients with COVID-19, male-dominated (60%) and aged between 46 and 55 years (50%). Data on potential drug interactions showed that 28 out of 30 patients had the potential to experience drug interactions in the categories of severe (9,23%), moderate (74,62%), and mild (16,15%).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom